Method for diagnosing diseases based on levels of anti-glycan antibodies

a technology of antibodies and glycans, applied in the field of diagnosis of diseases by detecting levels of antibodies to glycans, can solve the problems of reducing affecting the diagnostic accuracy of ibd and ibs, so as to facilitate earlier and more appropriate therapeutic intervention, reduce uncertainty for patients and their families, and high serological testing. the a technology of glycan antibody detection and diagnosis of diseases, a technology of glycan antibody detection and diagnosis of diseases, a technology of glycan and glycan and anti-glycan and glycan and anti-glycan and applied in the field of a method, which is applied in the field of a method of glycan and glycan and glycan and glycan level a technology of a technology of a technology of a technology of a technology of a glycan antibody detection and diagnosis method, applied in the field of a technology of a technology of a method, which is applied in the field of a method,

Inactive Publication Date: 2005-06-30
GLYCOMINKS LTD
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0010] Among the advantages of the invention is a highly sensitive serological testing method for definitively distinguishing CD from other digestive diseases, even when the inflammation is limited to the colon only. The highly sensitive primary screening assays according to the invention provide physicians with an inexpensive assay for rapidly distinguishing individuals with CD from non diseased individuals, or individuals having UC or IBS. This facilitates earlier and more appropriate therapeutic intervention and minimizing uncertainty for patients and their families.

Problems solved by technology

A primary determinant of these high medical costs is the difficulty of diagnosing digestive diseases.
The cost associated with IBD and IBS is compounded by lost productivity, with persons suffering from these disorders missing an average of at least eight more days of work annually than persons not suffering from these disorders.
This makes definitive diagnosis of CD extremely difficult.
In fact, only about one-tenth of the several million people suspected of suffering from CD are actually diagnosed with the disease The difficulty in differentially diagnosing CD from other digestive diseases like UC and IBS hampers early and effective treatment of these diseases.
When inflammation is limited to the colon, it can be very difficult to differentiate between UC or colon-restricted UC (which also known as CD colitis).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for diagnosing diseases based on levels of anti-glycan antibodies
  • Method for diagnosing diseases based on levels of anti-glycan antibodies
  • Method for diagnosing diseases based on levels of anti-glycan antibodies

Examples

Experimental program
Comparison scheme
Effect test

example 1

Comparative Antiglycan Antibody Levels in the Serum of Crohn's Disease Patients and Patients with Other Digestive Diseases

[0110] An anti-glycan antibody profile for IgG, IgA and IgM in the serum of the patients was obtained using GlycoChip® arrays (Glycominds, Ltd., Lod, Israel, Cat No. 9100). The arrays were constructed using procedures described in Schwarz et. al. Glycobiology, 13: 749-54, 2003. Anti-glycan antibody profiles of 45 CD patients and 27 patients with other digestive diseases were compared.

[0111] All serum samples were tested using GlycoChip® plates (Glycominds Ltd., Lod, Israel, Cat No. 9100), which was an array of mono and oligosaccharides covalently attached to a reduced volume 384-well micro titer plate. The mono and oligosaccharides displayed on the array are listed in Table 1. A translation of the LinearCode™ syntax used to describe glycan structure to IUPAC nomenclature can be found in Table 1.

[0112] The sera from patients volunteers who had signed an informe...

example 2

Comparative Antiglycan Antibody Levels in the Serum of Crohn's Disease (CD) Colitis Patients and Ulcerative Colitis (UC) Patients

[0119] An anti-glycan antibody profile for IgG and IgA in the serum of the patients was obtained using GlycoChip® arrays (Glycominds, Ltd., Lod, Israel, Cat No. 9100). The arrays were constructed using procedures described in Schwarz et. al., Glycobiology 13: 749-54, 2003. Anti-glycan antibody profiles of 6 CD colitis patients and 19 UC patients were compared. All serum samples were collected and tested as described in Example 1.

[0120] Tables 7 and 8 show the levels of IgG and IgA type antiglycan antibodies that were detected at significantly different levels between the CD Colitis population and the UC population. The values presented for IgG and IgA are absolute values. Comparison of the average and median values of anti-carbohydrate antibodies in the CD Colitis patients and UC patients populations reveals a significant elevation in most of the anti gl...

example 3

Comparative Antiglycan Antibody Levels in the Serum of Crohn's Disease (CD) Patients, Ulcerative Colitis (UC) Patients, and Irritable Bowel Syndrome (IBS) Patients

[0121] The levels of antiglycan antibodies in serum from CD, UC, and IBS patients were compared.

[0122] An anti-glycan antibody profile for IgG, and IgA in the serum of the patients was obtained using GlycoChip® arrays (Glycominds, Ltd., Lod, Israel, Cat No. 9100). The arrays were constructed using procedures described in Schwarz et. al. Glycobiology 13:749-54, 2003. The levels of the following Anti-glycan antibody were measured: Anti Laminarobioside (Glc(β,1-3)Glc(β)) Carbohydrate Antibodies (ALCA); Anti Chitobioside (GlcNAc(β,1-4)GlcNAc(β)) Carbohydrate Antibodies (ACCA); and Anti mannan (Anti Saccromyces Cervicia Antigen (ASCA)). Those antibodies were measured in the serum 70 CD patients, 56 UC patients and 19 patients with Non-IBD digestive diseases Controls (NIC) were also compared. All serum samples were collected a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
volumeaaaaaaaaaa
temperatureaaaaaaaaaa
gastrointestinal disorderaaaaaaaaaa
Login to view more

Abstract

Disclosed are methods for diagnosing Crohn's disease (CD) or anti-phospholipid Syndrome (APS) by measuring levels of antibodies to glycans in a biological sample.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of, and priority to, U.S. Ser. No. 10 / 728,227, filed Dec. 3, 2003. The contents of this application are incorporated by reference in their entirety.FIELD OF THE INVENTION [0002] The invention relates generally to a method for diagnosing diseases by detecting levels of antibodies to glycans in a subject. More particularly, the invention relates to methods for diagnosing digestive diseases such as Crohn's disease (CD), or anti-phospholipid syndrome (APS). BACKGROUND OF THE INVENTION [0003] Inflammatory bowel disease (IBD), which occurs world-wide and afflicts millions of people, is the collective term used to describe two gastrointestinal disorders of unknown etiology: Crohn's disease (CD) and ulcerative colitis (UC). IBD and irritable bowel syndrome (IBS) will affect one-half of all Americans during their lifetime, at a cost of several billion dollars. A primary determinant of these high medical costs is the difficulty o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/53G01N33/543G01N33/567G01N33/68
CPCG01N33/543G01N2800/065G01N33/6893G01N33/6854Y10S436/811Y10S435/942
Inventor DOTAN, NIRDUKLER, AVINOAM
Owner GLYCOMINKS LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap